GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells $36,200.10 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 402 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $90.05, for a total value of $36,200.10. Following the sale, the chief financial officer now owns 5,044 shares in the company, valued at approximately $454,212.20. This represents a 7.38 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Kevin Feeley also recently made the following trade(s):

• On Monday, March 17th, Kevin Feeley sold 3,749 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total value of $362,565.79.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The shares were sold at an average price of $94.72, for a total value of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total value of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The shares were sold at an average price of $93.82, for a total value of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The shares were sold at an average price of $76.04, for a total value of $108,737.20.

GeneDx Price Performance

GeneDx stock opened at $97.44 on Thursday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The firm has a market cap of $2.73 billion, a P/E ratio of -49.71 and a beta of 1.91. The business’s fifty day moving average is $84.59 and its two-hundred day moving average is $70.97. GeneDx Holdings Corp. has a 52 week low of $8.03 and a 52 week high of $115.60.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.66. The company had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. Equities research analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GeneDx

A number of institutional investors and hedge funds have recently bought and sold shares of WGS. MCF Advisors LLC lifted its stake in shares of GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after acquiring an additional 182 shares during the period. Sterling Capital Management LLC lifted its stake in shares of GeneDx by 877.8% during the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock valued at $27,000 after acquiring an additional 316 shares during the period. Global Retirement Partners LLC acquired a new position in shares of GeneDx during the fourth quarter valued at $28,000. Lazard Asset Management LLC acquired a new position in shares of GeneDx during the fourth quarter valued at $35,000. Finally, Comerica Bank acquired a new position in shares of GeneDx during the fourth quarter valued at $50,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the company. TD Cowen boosted their price target on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. The Goldman Sachs Group boosted their price target on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research note on Wednesday, February 19th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, GeneDx presently has a consensus rating of “Moderate Buy” and an average price target of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.